# Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

> **NCT00908037** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 82 (actual)

## Conditions studied

- Purpura, Thrombocytopaenic, Idiopathic

## Interventions

- **DRUG:** eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00908037
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-30
- **Primary completion:** 2014-02-01
- **Final completion:** 2014-02-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908037, "Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00908037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*